As a global healthcare provider, Novo Nordisk's key contribution is to discover and develop innovative medicines. Chief Science Officer Mads Krogsgaard Thomsen explains how we "innovate to improve the lives of people living with diabetes and other serious chronic diseases worldwide".
For decades, Novo Nordisk researchers have worked on oral delivery of peptides, and finally we have the evidence to support the specific mechanism for absorption of the peptide hormone GLP-1 in a co-formulation with SNAC (red staining on picture) in the stomach. The research findings were recently published in Science Translational Medicine.
We are looking to work with external partners that have complementary expertise to our own, both across our therapy areas and within each step of the pharmaceutical value chain.
Novo Nordisk's research and development facilities in Denmark, USA, UK, India and China form a global network that covers the entire pharmaceutical value chain across our therapy areas.